How many clinical trials are recruiting for lewy body dementia?

12 drug-interventional lewy body dementia trials are currently recruiting participants, out of 65 registered interventional trials.

Neurocognitive Disorders

Lewy body dementia drug pipeline

ICD-11 6D82
MeSH D020961

Subtypes: Lewy body dementia psychosis

Tracking the lewy body dementia drug-development landscape — clinical trials and emerging compounds.

Compounds in development

No compounds populated for this indication yet — see registered trials below.

Also in development for subtypes of Lewy body dementia

RemlifanserinPhase 2ACADIA Pharmaceuticals Inc.for Lewy body dementia psychosis

Trials recruiting now (12)

12 drug-interventional lewy body dementia trials recruiting now, of 65 registered interventional trials. Browse all on ClinicalTrials.gov →

Phase 4Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Galantamine HBr extended-release 8mg capsules (8mg ER).
Virginia Commonwealth Universityn=120United States · 1 siteStarted Dec 2025NCT07284290
Phase 4Comparing Antipsychotic Medications in LBD Over Time
Pimavanserin, Quetiapine
The University of Texas Health Science Center at San Antonion=94United States · 2 sitesStarted Apr 2022NCT05590637
Phase 352-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
ACP-204
ACADIA Pharmaceuticals Inc.n=126Bulgaria, Czechia +1 · 15 sitesStarted Nov 2025Tracked: Remlifanserin NCT07095465
Phase 318F-DOPA II - PET Imaging Optimization
Furosemide Injection
University of Albertan=800Canada · 1 siteStarted Jan 2021NCT04706910
Phase 2A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab, Placebo
Eli Lilly and Companyn=350Japan, South Korea +2 · 72 sitesStarted May 2026NCT07589595
Phase 2A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
ACP-204, Placebo
ACADIA Pharmaceuticals Inc.n=180Bulgaria, Czechia +4 · 56 sitesStarted Aug 2025Tracked: Remlifanserin NCT07029581
Phase 2Safety and Efficacy of AR1005 in Patients with Lewy Body Disease
AR1005, Placebo, Rivastigmine 3 mg
Yonsei Universityn=60South Korea · 1 siteStarted Jan 2024NCT06537076
Phase 2Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
Ambroxol, Placebo
Helse Fonnan=180Norway · 8 sitesStarted May 2021NCT04588285
Phase 1/2Terazosin for Dementia With Lewy Bodies
Terazosin Hydrochloride
Qiang Zhangn=40United States · 1 siteStarted Oct 2027NCT04760860
Phase 1/2Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
Ambroxol Hydrochloride
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sn=15Canada · 1 siteStarted Jan 2025NCT04405596
Phase 1hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
hUC-MSC-sEV-001 nasal drops
Xuanwu Hospital, Beijingn=120China · 1 siteStarted Jul 2025NCT06607900
Phase 1[18F]F-DOPA Imaging in Patients With Autonomic Failure
Carbidopa 200mg oral dose, Entacapone 400mg oral dose
Daniel Claassenn=40United States · 1 siteStarted Feb 2020NCT04246437

Frequently asked

How many clinical trials are recruiting for lewy body dementia?: 12 drug-interventional lewy body dementia trials are currently recruiting participants, out of 65 registered interventional trials.